ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.
